At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and diverse pipeline with the potential to impact cancer and orphan diseases through our single domain antibody platform technology. Single domain antibodies (sdAbs) provide a small, simple, modular target binding domain that can be combined in a variety of ways to meet specific needs of unique biological targets. Our sdAb-based therapeutic candidates have been designed to interface with the biology of each target antigen, and can be readily manufactured at high yields with established processes. We have created various multivalent and multispecific therapeutic formats that are each designed to achieve unique functions, including the ability to:
- effectively cluster receptors with precisely defined valency;
- simultaneously engage multiple antigens or epitopes;
- combine synergistic functions in a single molecule; and
- restrict therapeutic activity to the tumor microenvironment or other biologically distinct tissue.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $40M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | RA Capital... | racap.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.05.2019 | IPO | $40M | - |
Mentions in press and media 19
| Date | Title | Description | Source |
| 13.03.2024 | SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KAMN, JNPR... | - | globenewsw... |
| 05.01.2022 | Inhibrx Announces Initial Phase 1 Dose Escalation Results fo... | SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with f... | marketscre... |
| 02.12.2021 | Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 i... | SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with f... | marketscre... |
| 03.11.2021 | Inhibrx Announces Presentations at SITC 2021 | SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with f... | marketscre... |
| 01.11.2021 | Inhibrx Announces Participation in Upcoming Scientific and I... | SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with f... | marketscre... |
| 13.09.2021 | Inhibrx : Announces Participation in Upcoming Investor Confe... | SAN DIEGO, Sept. 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnolo... | marketscre... |
| 13.09.2021 | Inhibrx Announces Participation in Upcoming Investor Confere... | prnewswire... | |
| 21.06.2021 | INHIBRX, INC. Inhibrx : Initiates a Potential Registration-... | SAN DIEGO, June 21, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with ... | marketscre... |
| 21.06.2021 | Inhibrx Initiates a Potential Registration-Enabling Phase 2 ... | prnewswire... | |
| 17.05.2021 | Inhibrx Announces Participation in Upcoming Investor Confere... | prnewswire... |
Show more